Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS3279996 A
Type de publicationOctroi
Date de publication18 oct. 1966
Date de dépôt28 août 1962
Date de priorité28 août 1962
Autre référence de publicationDE1467861A1
Numéro de publicationUS 3279996 A, US 3279996A, US-A-3279996, US3279996 A, US3279996A
InventeursFolkman Moses Judah, Jr David M Long
Cessionnaire d'origineFolkman Moses Judah, Jr David M Long
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Polysiloxane carrier for controlled release of drugs and other agents
US 3279996 A
Résumé  disponible en
Images(1)
Previous page
Next page
Revendications  disponible en
Description  (Le texte OCR peut contenir des erreurs.)

Oct 18 1966 y D. M. LQNG, JR., ETA

POLYSILOXANE CARRIER FOR CONTROLLE B RELEASE DRUGS AND OTHER AGENTS Filed Aug. 28, 1962 INTENSITY OF BEAT TIME INTERVAL IN 0.2 SECOND-" INVENTORfr DAVID M. LONG JR. MOSES JUDAH FLKMAN BY fl-J/Mm/L/ ATTORNEY United States Patent 0 3,279,996 PGLYSHLGXANE CARRIER FOR CONTRGLLED RE- LEASE 0F DRUGS AND OTHER AGENTS David M. Long, In, Boston, Mass. (1028 Rand Road,

Villa Park, Ill. 60101), and Moses Judah Folkman,

Boston, Mass. (24 St. Marys St., Newton Lower Falls,

Mass. 02162) Filed Aug. 28, 1962, Ser. No. 220,105 16 Claims. (Cl. 167-82) The invention described herein may be manufactured and used by or for the Government of the United States of America for governmental purposes without the payment of any royalties thereon or therefor.

Our invention relates generally to a method and means for introducing a therapeutic agent into a living organism and more particularly, it relates to a polysiloxane carrier that allows for controlled release of drugs and other agents within a specified region or organ of the body.

In the past, drugs or pharmaceutical preparations have been mixed with carrier agents, such as beeswax, peanut oil, stearates, etc., and injected intra-muscularly into the body. The carrier is then slowly broken down within the body allowing a slow release of the drug. Such carriers do not give satisfactory results because they often produce undesirable effects, such as foreign body reaction and scar formation; in addition, granulomas (benign fibrous tumors) and sterile abscesses are formed at the site of the injection. In most cases the rate of release of the therapeutic agent is so rapid that frequent injections become necessary with only small amounts of active agent in each injection. Furthermore, the bulk of the carrier substance limits the amount of active agent that may be used in each injection. A further practical drawback to this form of introducing medication follows from the fact that injections are active for only a few days or a week.

Heretofore, containers of many types have been designed for use within the body cavities whereby medical preparations are allowed to escape from the containers through tiny openings or perforations. Experience has proven that the tiny openings and perforations are rapidly plugged with body tissues, and the dispensing action ceases in a matter of hours or a few days. More elaborate arrangements for depositing medication within the body, involved the use of a dense tablet form which is formed with a smooth, compact surface, a portion of said surface is covered with a protective, undissolvable coating, while the remaining surface of tablet is exposed to the action of the body fluids. Obviously, resorption of medication from an exposed surface in which the medicinal substance is accessible to fluids cannot be definitely controlled or predicted during dissolution of the entire tablet.

We have now discovered a method for introducing therapeutic agents into the body by means of a novel implantate that is capable of providing a uniform release of powerful drugs for long periods, as much as several years. The novel implantate can release the desired amount of active agent directly into a malfunctioning organ for immediate use and at a constant dosage rate, without interruptions or variations in the supply as is generally the case with all of the previous methods noted above. Unlike the common practices of administering medication, orally or by injections, we now provide a method in which the :active agent does not encounter an uncertain course through the fluid streams in order for it to reach the area of its utility. Instead, the desired medication is made readily available in situ from an implanted carrier which releases the active agent in relatively minute amounts yet cumulatively the agent released in a sustained time interval may reach any effective dosage level. The novel carrier of our invention can also be maintained within the body as an active dispenser of medication throughout the body system and to function effectively for prolonged periods without ill effects, whereby the implanted carrier becomes virtually an artificial gland.

It is an object of the present invention to provide a method and means for implanting a drug or other agent within an organ or region of the body for relatively slow, prolonged release thereof at a constant rate.

Another object of the present invention is to provide a novel drug carrier which can be implanted into the body for long term, direct application of a drug without the disadvantages of frequent injections or by way of digestion and absorption.

Another object of the invention is to provide a chemical pacemaker for regulating the functions of the heart by means of a slow, prolonged release of a powerful drug.

A further object of the invention is to provide an implantate within the body that releases a drug at a predetermined rate based upon pharmaceutical requirements.

A still further object of the invention resides in the use of a carrier within the body for slow prolonged release of a dry, powdered drug in situ thereby preserving the drug in its more stable form until it is made available to the body.

And yet a further object of the invention is to provide a substantial increase in efficiency in the use of drugs and other agents which have a beneficial effect for a certain organ or region of the animal organism, by encapsulating said drugs to dispense them directly in the designated organ or body region at a therapeutic nate.

Still further objects and advantages of the present invention will appear from the following detailed description taken in connection with the accompanying drawings, in which:

FIG. 1 is a perspective view, partly in section, of a preferred embodiment of the present invention;

FIG. 2 is a perspective view illustrating a modification of the drug carrier shown in FIG. 1;

FIG. 3 shows a further modification of the invention in which the implantate is in the form of an artificial aortic valve;

FIG. 4 shows a oardiograph of a heart beat indicating restored heart function as a result of an implanted drug carrier; and

FIG. 5 shows a drug carrier in accordance with the invention implanted in the muscle of the heart.

We have discovered in accordance with the present invention that a drug carrier may be formed in the shape of a container, capsule, or medicated solid which contains within an enclosed space or structure thereof a suitable drug for the purpose of implanting said carrier and drug within a living organism. Specifically, the capsule or other carrier is implanted within the tissues of an organ or in a particular region of the body for controlled release of the drug at a substantially constant level of dosage and for a long duration. The term drug is used in the specification and claims hereof in its broad sense as synonymous to therapeutic agent, medicament and the like, and it is to be understood that all of such terms are intended to be inclusive of hormones, vitamins, antibiotics, anticoagulants, cancericidal agents, spermicidal agents, vasoactive agents and other medicinals and medications effective to treat undesirable conditions existing in or on an animal body or in the body fluids.

A preferred form of our invention comprises a drug carrier formed of an organopolysiloxane rubber composition (more generically known as a silicone rubber), which is non-reactive toward the drug, non-toxic to the body, and known to be compatible with living tissue even after prolonged implantation in the living organism. The silicone can be either a conventional silicone rubber, or a composition chaarcterized by room temperature vulcanizing, i.e., RTV silicone rubber. Either form of silicone rubber can be fabricated into a suitable container, such as hollow tubing, capsule, pellet and the like, or alternately, the silicone rubber may be formed into a prosthetic device capable of retaining within its polymer structure a suitable medication. Another embodiment of our invention is the direct injection of an RTV silicone rubber-drug fluid mixture into a body tissue, as explained in greater detail further on in the specification.

The silicone rubber carrier in accordance with the present invention permits slow passage or diffusion of the drug contained therein to the outer surface of the polymer wall where it is absorbed by the body fluids. The drug is preferably used in the dry, powdered form, since the solid form as a rule is found to be more stable, and the drug composition is thus advantageously stored within the body until it is released from the polymer carrier.

The invention in its broadest aspect is directed to the phenomenon of diffusion in which a powder, semi-solid or liquid migrates through a polymer wall at a relatively low rate. The mechanism by which diffusion or migrating action is achieved, may be explained on the basis of a gradient effect in which the enclosed substance relieves its internal concentration by spreading out into the adjacent medium. This action ordinarily would cease when suflicient substance has reached the outer surface or boundary of the adjacent medium. In the present case, however, the migrant molecules are advantageously being removed from the outer surface of the polymer wall by body fluids and by tissue absorption, and the migrating action continues indefinitely, or until the migrant medicinal substance has been completely consumed.

The powders, semi-solids, etc. which are capable of penetrating the polymer wall are generally those that show appreciable solubility in the polymer composition. More-over, the ease with which these substances pass interstitially between elastomer molecules will depend to a great extent on the silicone rubber composition which is utilized in the drug carrier.

As noted above, the silicone rubber employed in this invention can be either a conventional one or an RTV type. These rubbery products are now well known in the art.

By conventional silicone rubber we refer to those sytsems which are converted to the rubbery state (i.e., they are cured or vulcanized) by the action of heat. The silicone polymers in such systems are predominantly linear organopolysiloxanes, having a preferred average degree of substitution of from about 1.98 to 2.02 organic groups attached directly to silicon (by carbon-silicon linkage) per silicon atom. The organic groups attached to silicon are preferably monovalent hydrocarbon radicals such as alkyl, aryl, alkenyl, alkaryl and aralkyl, and of these the methyl, phenyl, and vinyl radicals are most preferred. Halogenated monovalent hydrocarbon radicals may also be present as the organic groups in the silicone polymer, typical examples being chl-orophenyl and 1,1,1-trifluoropropy1 radicals.

Variation of the organic groups in the silicone polymer can be used to vary the solubility of the drug in the polymer, and hence can to some extent control the speed of migration of the drug through the polymer. Also, drugs which are insoluble in one type of polymer may be soluble in a different type of polymer. It is obvious that the choice of organic substitution in the polymer should take into consideration any slightly toxic or foreign body reactions brought about by the presence of that polymer in the body. Pure dimethylpolysiloxanes and dimethyl-polysiloxanes which have a minor amount (for example, up to about 0.5 molar percent) of methylvinylsiloxane units present have been studied more extensively from the toxicological standpoint than any others and have been. found to be completely inert in the body, ence these are the most preferred polymers for use in our invention. There are some uses of our invention which are outside of the body, however, and in such cases any foreign body reaction which might be characteristic of a particular polymer would be of little or no concern.

The conventional silicone rubber formulation usually contains a filler to enhance the tensile strength and other physical properties of the cured rubber. Many types of such fillers are Well known in the art. The socalled reinforcing silica fillers develop the best propertics, however, and silicone rubber containing them has been found to be inert in extensive studies involving implanting the rubber in many different body tissues. For these reasons, the silica fillers are preferred. Examples of reinforcing silica fillers include silica aerogel, fume silica, and other forms of silica having a relatively high pore volume and surface area. If desired, the silica fillers can have organosiloxy groups attached to the surface thereof through siloxane bonding to improve the handling properties of the uncured silicone rubber formulation.

It is typical of the conventional silicone nubber formulations that they contain a peroxy vulcanizing agent. Again a host of suitable agents is known to the art, but when our invention is to be used by implanting the silicone rubber within the body, we prefer the use of benzoyl peroxide or dichlorobenzoyl peroxide. These agents decompose during the vulcanization and are not present in the finished rubber.

The patent literature showing the preparation of the above discussed silicone rubber is extensive. Illustrative US. patents include Warrick No. 2,541,137, K-onkle et al. No. 2,890,188, Youngs No. 2,723,966, Tyler No. 2,863,846, and Johannson No. 3,002,951.

The RTV silicone rubbers are also commercially available materials and are known to the art. In general they employ the same silicone polymers as discussed above (although the polymers often contain a greater amount of silicon-bonded hydroxy groups by being deliberately endblocked with such groups). The fillers discussed above can also be used if fillers are desired, and the cross-linking is achieved by introducing components such as the orthosilicates, polysilicates, and siloxanes containing silicon-bonded hydrogen atoms. This type of silicone rubber formulation will cure at room temperature when an appropriate catalyst is added, thus it is at least a two component system in which the catalyst is added just prior to use of the product. Typically the catalysts are metal salts of canboxylic acids, and when the invention is to be used by implanting the silicone rubber within the body, stannous 2-ethylhexoate is the preferred specie of catalyst.

It is sometimes desirable to inoonponate or attach a silicone rubber sponge composition in the silicone rubber drug-carrier to be used as an anchoring means for the implanted unit, as described in greater detail below. The sponged or foamed type of silicone rubber is also a commercially available product, and can be obtained in an RTV form. Such systems generally employ an organosiloxane polymer containing a relatively great amount of siliconabonded hydroxy groups, another organopolysiloxane polymer containing silicon-bonded hydrogen atoms, and fillers and metal salt catalysts as in the previously discussed RTV systems. In this case, the catalyst not only brings about a conversion to the rubbery state, but also releases hydrogen gas from the hydrogen substituted polymer, this gas being the sponging or foaming agent for the system.

Another commercially available RTV silicone rubber which can be used in this invention to form a solid (i.e., non-sponged) rubber product is a one component system in the sense that no catalyst need be added. In this system, the silicone polymer employed is one which contains two acyloxy group's (preferably acetoxy groups) attached to terminal silicon atoms. The usual fillers can be present in this type of product. When exposed to atmospheric moisture, the acyloxy groups hydrolyze to form new trifunctional siloxane units within the polymer which act as the cross-linking bridges necessary to produce the final rubbery product.

The vanious RTV silicone rubber products discussed above can be prepared as described in detail in, for ex ample, US. Patents No. 2,927,907 (Polmanteer) and No. 3,035,016 (Bruner), and in British Patents No!. 798,669 and No. 804,199.

The silicone rubber may bemolded into a capsule or pellet having any convenient wall thickness and containing therein a drug or active agent-one which has bee found to be capable of diifusing into and permeating the silicone rubber wall--the capsule or pellet having a surface substantially free of pores, perforations or semipermeable surface areas. The drug molecules included therein will have a definite or characteristic rate of diffusion through the container wall, which will in effect establish the dosage rate and the amount of drug which is released from a coherent surface in a given time interval. Thus, the amount of drug which is released over an extended period is based on the rate at which the drug diffuses through the silicone rubber and also on the ability of the living tissues in the body to absorb the drug from the surface of the container. By limiting the transference surface of the container, as will be explained presently in greater detail, the amount of drug that reaches the surface may be eifectively controlled.

The novel implantate may be varied in many ways, but it is most desirable to shape the dispensing drug carriers into tubular form of given lengths and volume capacity and having a calibrated rate of release for specified drug compositions. Hollow, tubular cartridges or capsules molded into a continuous, uniform dispensing surface and incorporating therein a preferred quantity of active agent may be made available to the medical and surgical profession as standard dispensing units. If it is desired to decrease the amount of drug which is to be released in a given period, a portion of the dispensing silicone rubber surface may be coated with a more impervious plastic substance to limit the effective transference area from which drug diffusion and absorption can occur. Alternately, a tubular container may be provided with an inner metallic or plastic casing having a number of port holes of a given dimension through which diffusion and transference action of the contained drug may be substantially regulated. Standard implantates of a specified length will provide a prescribed dosage of drug during a 24-hour interval. The implantates may also be designated in terms of desired physiological effects which they are capable of producing: A heart drug in a given tubular length may be prescribed as capable of generating on the average a given number of heart beats, for example, 70, 80, or 90 heart beats per minute.

Desirably, in carrying out the present invention, hollow, tubular containers are formed of silicone rubber having a wall thickness sufficient to provide a resilient tubular structure that is self-supporting and that does not collapse or bend while implanted Within the tissues of the body. While the thickness of the container determines initially the time interval which is required for the drug molecules to penetrate the polymer wall, the thickness of the silicone rubber does not affect the dispensing rate of the present carrier. After the drug has penetrated the 6 wall, the migration of drug molecules is primarily a function of the solubility of the drug in the silicone rubber composition, and they will in effect penetrate a thin or thick wall at substantially equal rates.

It is also advantageous to provide polysiloxane carriers in the form of prosthetic devices for the body into which medication is incorporated by any suitable means. For example, anti-coagulants, such as heparin or Versene (ethylenediaminetetraacetic acid) may be impregnated into vascular or intravascular prostheses in order that their relatively slow rate of release from the carrier will provide sufficient protection against thrombosis. The medication may be introduced into the polysiloxane composition during the forming process of the device, or it may be diifused into the finished product. For example, the drug carrier may be formed by immersing the prosthetic device into a saturated solution of herapin, Versene, or other drug in a suitable solvent, such as alcohol, acetone, xylene or water.

Further modifications in the formation of drug carriers involves the use of relatively fluid polysiloxane of the RTV type and a medication dissolved therein. The fluid mixture is injected into the tissues along With a catalyst to cause the fluid polysiloxane to polymerize in situ and form a solid implant capable of providing a relatively slow release of medication. A mixture of parts by weight of a fluid hydroxy end-blocked dimethylpolysiloxane (having a viscosity of about 10,000 centistrokes 25 C.) and 3 parts of ethylpolysilicate may be combined with 250 grams of penicillin and a suitable catalyst, for example, sta-nnous Z-ethylhexoate in an amount of about 0.5 percent based on the weight of the fluid polysiloxane. After the injected mixture has polymerized to a solid state, the penicillin is released slowly within the tissues. Fillers can be omitted from the injectable RTV material because strength of the rubber is not important. The presence of fillers, however, is not objectionable as long as an injectable consistency remains in the fluid.

In connection with the embodiments of the invention illustrated in the drawing, the drug carrier of FIG. 1 is a length of silicone rubbing tubing 1, shown in cross-section as comprising a wall 2 and a confined space 3 containing therein an active agent 4, for example, dry vitamin B powder. The ends of the tubing are sealed with an RTV silicone rubber 5. The latter consists of methyldiacetoxysilyl end-blocked dimethylpolysiloxane fluid, and a fume silica filler. A period of about 24 hours is necessary for the seals to cure. A specific example of a carrier formed in this manner comprises about 1 cm. length of silicone rubber tubing having an inside diameter of 0.140

inch and a wall thickness of 0.030 inch. This rubber was prepared by extruding a mixture of about 75 parts polymer, 24 parts fume silica and 1 part 2,4-dichlorobenzoyl peroxide. The mixture was cured 30 seconds at 730 F. and vulcanized by heating for 2 hours at 400 F. The polymer was a dimethylpolysiloxane containing about 0.14 mole percent methylvinylsiloxane units copolymerized therewith. The tubing is filled with about 20,000 micrograms of tri-iodothyronine.'

By utilizing the means set forth above, implantates have been employed in the body and the desired effects produced have been quantitatively correlated. A drug carrier produced in the manner described and containing 10,000 micrograms of a triiodothyronine in a silicone rubber tube having a length of 14 mm. will release approximately 10 micrograms of the drug in a 24-hour period and generally provide a heart rate in a dog of about beats per minute. When a drug carrier 24 mm. long is used in the same manner and containing the same drug, it will release approximately 30 micrograms in a 24-hour period, and the heart beat is stepped up to about 200 beats per minute.

An implantation involving the use of a heart drug is performed by surgery and involves the insertion of a polysiloxane capsule containing a relatively large amount of dry powder. A capsule containing 30,000 micrograms of digitoxin may be safely utilized within the body without any undue or irregular release of drug. The capsule containing the drug is initially sterilized and all surface digitoxin that may have been released to the surface is carefully removed. The capsule is then implanted by surgery in the myocardium of the heart. The digitoxin is released at a rate of about micrograms per day producing an excitable focus on the heart. This focus then drives the heart at nearly physiologic rates. There is no systemic effect from the use of the drug since it is released in very low concentrations. It is axiomatic that the drug is dispensed in such low concentrations yet has been found to be effective because the entire drug released in this manner is utilized directly within the heart area. Moreover, the drug need not be sterilized, since migration through the polymer Wall involves molecular size whereas bacteria are many order of magnitude larger and are effectively screened out.

The embodiment of FIG. 2 illustrates the use of an open cell silicone rubber sponge layer 6 attached to the capsule surface 1 by any suitable means, as for example, by slipping a sponge sleeve 6 over the capsule surface. The sponge layer has been found to serve as an anchoring means for the capsule within a cavity created in the tissue to receive the capsule; the sponge expands in the cavity and prevents movement of the capsule. Moreover, it serves as a matrix for the absorption of fluid, fibrin or connective tissue in the surrounding areas after implantation. Finally, the sponge layer also acts as a wick for the transport of drug from the capsule surface to the muscle site.

As pointed out above, it is possible according to the invention to fabricate a silicone rubber prosthesis, as the aortic valve, shown in FIG. 3 in which an anti-coagulant may be impregnated into the prothesis material to protect the valve from thrombi formation.

By utlizing a silicone rubber carrier within the myocardium of the heart, an excitable focus is produced, as shown in the cardiograph record of FIG. 4. Prior to an implant surgery on a dog with complete heart block, a fixed heart rate of approximately 55 beats per minute is indicated at A. After a sealed silicone rubber tubing (as above described and being approximately 17 mm. long) containing 20,000 micrograms of tri-iodothyronine powder was implanted through an incision 7 in the left ventricle of the heat, as shown in FIG. 5, a heart rate of 150 beats per minute was generated. The electrocardiograph indicates at B the impulses arising from the site of the implant, about 8 hours following the implantation.

The implantate may in some cases provide a basal level of drug, while additional dosages may be supplemented by oral medication or by injection. Thus the drug requirements of a patient may be more effectively controlled by providing some of the drug requirement from the implantate, while the practitioner can increase or vary the 1nedication by means of supplemental doses.

Heating increases the diffusion rate so that a capsule which has been heated will start diffusion of medication more rapidly. The capsule may also include more than one drug, one drug which diffuses rapidly becomes quickly available to the body, while a less diffusable drug becomes available at a later time, after the first drug has served its purpose.

Whereas the novel implantate has been described above with reference to its use in dispensing drugs in the living tissues of animals, such as dogs, evidence developed in our work indicates an equally effective use of the implantate in the human body.

Our method of introducing drugs into the living organism provides a drug carrier which is readily tolerated in living tissues and which does not deteriorate by implantation in the living body. Therefore, the drug carrier may be implanted within the organ or body region to be treated to provide constant release of the drug directly within the region in which it will produce the desired beneficial effect. For example, a capsule containing dry nitrogen mustard may be implanted in (or adjacent to) a cancerous mass.

It is now feasible to utilize drugs of more suitable compositions that are more effective within a specified body region and that eliminate extraneous injection media and oral preparations that masked or merely accommodated the active therapeutic agent in its course through the body. More effective therapeutic agents 'with greater physiological activity are now contemplated as a result of this invention, whereas the previous methods of administration were not able to utilize them in their active form. For superior results can be achieve-d by our method since the active drug composition is not mixed with a carrier agent thus avoiding any interaction between the active drug and the carrier. In prior art methods the active agent was often combined chemically with an inactive carrier molecule which had to become separated in vivo before the active agent could be used in therapy. In accordance with the present invention, however, it is possible to utilize the most powerful drug in direct application in any desired concentration for immediate results without the precarious course of the previous carriers.

Another important advantage of the present invention is that the silicone rubber implantate is not dependent upon the gradual decomposition or removal of the carrier. The container or capsule remains intact and unchanged. In the previous methods, the active molecule mus-t initially be detached and freed from the carrier as is the case with the use of beeswax or peanut oil, in order for the drug agent to regain its therapeutic effect.

The drug employed in the present silicone rubber carrier remains dry even with implantates that have been in use in the body for many months. Thus it can be readily appreciated that this method is specifically important for compounds that are highly unstable in the wet form and which could not be utilized effectively by previous means of implantation or injection.

It is also within the purview of the present invention to employ a container made of silicone rubber composition, as described'herein, which incorporates within the composition a suitable anti-coagulant, such as heparin or Versene. As is now apparent from the previous discussion, desirable and beneficial results can be attained by means of the novel container in storing and preserving whole blood. The undesirable effect of coagulation, which occurs when the blood is removed from its normal environment in the living organism, is effectively suppressed by placing the blood in a silicone rubber container that has been impregnated with an anti-coagulant. The minimal daily release of anti-coagulant from the container composition will prevent coagulation and thus preserve Whole blood in its normal state without the usual practice of preserving the blood in ACD solution or by excessive use of anti-coagulants.

The silicone rubber container of the present invention is use-d to dispense minimum daily amounts of anti-coagulant to the blood thereby obviating the need for large amounts of preservatives. The blood may now be stored for periods of up to 21 days in its normal state, and preferably in accordance with the preferred practice at a temperature of about 4 C., and utilized directly in blood transfusions and for other purposes which require normal, whole blood, relatively free of foreign substances.

The invention may be utilized in connection with drug carriers containing any desired medical or pharmaceutical type illustrated for example by any of the anti-infectives. Such preparation include antibacterial-s, i.e., sulfathiozole; antibiotics, i.e., penicillin; antifungal agents; i.e., Nystatin; antimalarials, i.e., atabrine and the antiprotozoans, i.e., hydroxystilbamide isothionate. Antineoplastic agents, which include, for example, nitrogen mustard, previously mentioned in the specification; cardiovascular agents, which include digitalis, quinidine and nitroglycerine; con- 9 traceptives, for instance spermicidal agents such as hexylresorcinol, may also be utilized in accordance with the present invention. Hormones and the synthetic substitutes and antagonists as represented by the thyroid hormones and by insulin may be used with beneficial results. Immunological agents including for example, tetanus toxoid, renal acting agents, for example, acetozolomide, skeletal muscle relaxants and their antagonists, for example, Mephenesin, central nervous system stimulants, for example, ephedrine; and central nervous system depressants, which include the barbiturates in all their various chemical modifications are also included in the invention. Anesthetics which may be used in the novel drug carrier, include procaine, an antihistamine, i.e., benadryl; a detoxicant, dimercaprol; an enzyme, i.e., hyaluronidase and an agent affecting blood formation, i.e., liver extract. A radioactive isotope which may be included in the novel carrier is iodine 131-tagged albumen. Specific proteins find utility in accordance with the invention, as represented by gamma globulin.

Examples of additional drugs which may be included in the present drug carriers with beneficial results in accordance with this invention include adrenal corticotrophic hormone; adrenal cortical hormones, such as aldosterone, desoxy corticosterone, hydrocortisone and cortisone; parathromone, pituitrin, testosterone.

While we have described our invention in conjunction with certain drugs and specific implantate structures, it will be realized that these materials and structures may be varied without departing from the spirit and scope of the invention, which is the method and means of introducing drugs into the body from a dense-surface, plastic implantate over a prolonged period. The drugs and silicone rubber carrier can be varied to provide various dosage rates of selected drugs that provide a large number of physiological and therapeutic requirements. Other variations which do not depart from the spirit of the invention will occur to those skilled in the art.

What is claimed is:

1. An implantate for releasing a drug in the tissues of a living organism comprising a drug enclosed in a capsule formed of silicone rubber, said silicone rubber making limited area contact with said drug, said drug being soluble in and capable of diffusing through said silicone rubber to the outer surface of said capsule at a constant rate.

2. A drug carrier capable of releasing a drug at a constant rate when implanted in a living organism comprising a drug enclosed in a sealed container formed of silicone rubber, said drug being soluble in and capable of diffusing through the silicone rubber to the outer surface of said container at a constant rate.

3. A drug carrier capable of releasing a drug at a constant rate when implanted in a living organism comprising a prosthesis formed of silicone rubber, said prosthesis containing therein a drug which is soluble in and capable of diffusing through said silicone rubber to the outer surface of said prosthesis at a constant rate.

4. An implantate for releasing a drug in the tissues of a living organism comprising a drug dispersed in a silicone rubber which has been vulcanized in situ in said tissues, said drug being soluble in and capable of diffusing through said silicone rubber to the outer surface thereof at a constant rate.

5. An implantate for releasing a drug in the tissues of a living organism comprising a capsule formed of silicone rubber, said silicone rubber consisting essentially of dimethylpolysiloxane, and a drug enclosed in said capsule which is soluble in and capable of diffusing through said silicone rubber to the outer surface of said capsule ata constant rate to the outer surface of said capsule at a constant rate.

6. An implantate for releasing a drug in the tissues of a living organism comprising a capsule formed of estrodiol, progesterone and silicone rubber, said silicone rubber consisting essentially of an organopolysiloxane which contains on the average from about 1.98 to about 2.02 organic groups per silicon atom, said group being selected from the radicals consisting of monovalent hydrocarbon radicals and halogenated hydrocarbon radicals, and a drug enclosed in said capsule which is soluble in and capable of diffusing through said silicone rubber to the outer surface of said capsule at a constant rate. 0

7. An implantate for releasing a drug in the tissues of a living organism comprising a capsule formed of silicone rubber, said silicone rubber consisting essentially of dimethylpolysiloxane, which contains on the average from about 1.98 to about 2.02 organic groups per silicon atom, and up to 0.5 mol percent of methylvinylpolysiloxane, and a drug enclosed in said capsule which is soluble in and capable of diffusing through said silicone rubber to the outer surface of said capsule at a constant rate.

8. A drug carrier capable of releasing a drug at a constant rate when implanted in a living organism comprising a sealed, tubular container and a drug enclosed in said container, said container being formed of a section of silicone rubber tubing and the ends of said tubing being sealed with a layer of silicone rubber, said drug being soluble in and capable of diffusing through said silicone rubber tubing to the outer surface thereof at a constant rate.

9. The method of introducing a drug into an animal body which comprises injecting within a region of said body a mixture of a drug with an organopolysiloxane fluid which undergoes vulcanization at room temperature to silicone rubber, said drug being soluble in and .capable of diffusing through the silicone rubber to the outer surface thereof at a constant rate.

10. A drug carrier in accordance with claim 8 in which the silicone rubber of said end-sealing layers is formed of cured methyldiacetoxysilyl end-blocked dimethylpolysiloxane and contains a fume silica filler.

11. An implantate in accordance with claim 5 in which the silicone rubber contains a reinforcing silica filler.

12. A drug carrier which is capable of releasing a drug at a constant rate comprising a sealed, tubular container and a drug within said container, said container being formed of a silicone rubber tubing having an inside diameter of about 0.140 inch and a wall thickness of about 0.030 inch, the ends of said tubing being sealed with a silicone rubber composition, said drug being soluble in and capable of diffusing through said silicone rubber tubing to the outer surface thereof at a constant rate.

13. A drug carrier in accordance with claim 2 including a layer of silicone rubber sponge on the outer surface of said container, said sponge having an open cell structure to provide fluid access to said surface.

14. A method of introducing a drug into an animal body which comprises implanting within the living tissues of said body a capsule formed of silicone rubber and containing a drug which is soluble in and capable of diffusing through said silicone rubber to the outer surface thereof at a constant rate, and allowing said capsule to remain therein for a desired time interval to provide a controlled release of said drug through said silicone rubber.

15. A method of preserving Whole blood with a minimum amount of anti-coagulant which comprises placing said blood in a container formed of silicone rubber, which is impregnated with a solid anti-coagulant composition soluble in and capable of diffusing through said siilcone rubber to the outer surface thereof at a constant rate and storing said blood in said container, said silicone rubber providing a relatively low rate of release of said composition sufiicient to prevent coagulation during storage.

16. A container for storing whole blood comprising a silicone rubber vessel in which the silicone rubber is impregnated with a solid anti-coagulant composition soluble in and capable of diffusing through said silicone rubber to the outer surface thereof at a constant rate to provide a relatively low rate of release of said composition sufficient to prevent coagulation of said blood during storage.

References Cited by the Examiner UNITED STATES PATENTS Goldman 128-272 Yen et al. 167-82 Polin 206-5 Erikson 206-5 Cole 206-5 Feinstone 167-82 Levesque 167-82 Barton et a1. 128-272 12 OTHER REFERENCES J.A.P.A., vol. 46, No. 12, December 1957, pp. 705720.

M-cGregor: Silicones in Medicine and Surgery, DOW Corning Corp., Midland, Michigan, 1957 (44-page booklet) pp. 21, 23, 24, 28, 34, 35, 41, and 43 relied on.

The Bulletin, vol. 3, No. 1, Dow Corning Corp., Midland, Michigan, January 1961.

The Bulletin, vol. 4, No. 3, Dow Corning Corp., Midland, Michigan, July 1962.

JULIAN S. LEVITT, Primary Examiner.

FRANK CACCIAPAGLIA, Examiner.

G. A. MENTIS, Assistant Examiner.

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US2504482 *17 juin 194918 avr. 1950Premo Pharmaceutical Lab IncDrain-clear container for aqueous-vehicle liquid pharmaceutical preparations
US2512192 *26 mai 194820 juin 1950American Cyanamid CoSilicone resin medicament coating
US2846057 *9 févr. 19545 août 1958Polin Herbert SpencerDevices for dosage control
US2855933 *4 avr. 195214 oct. 1958American Hospital Supply CorpFluid receptacle
US2895475 *3 déc. 195621 juil. 1959Everett L ColeContainer for collecting, storing and dispensing biological fluids
US2951011 *17 déc. 195630 août 1960Feinstone Wolffe HarrySilicone composition for the relief of gastro-intestinal distress and method of using same
US2987445 *10 oct. 19586 juin 1961Rohm & HaasDrug composition
US3105613 *9 mai 19601 oct. 1963Baxter Don IncBlood container
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US3365728 *18 déc. 196430 janv. 1968Edwards Lab IncUpholstered heart valve having a sealing ring adapted for dispensing medicaments
US3371352 *19 janv. 19655 mars 1968Edwards Lab IncHeart valve for quick implantation having provision for ingrowth of tissue
US3499445 *16 août 196610 mars 1970Phytogen Prod IncAnimal husbandry
US3511684 *17 mai 196712 mai 1970Abbott LabMethod of treating polymeric resin to display nonthrombogenicity
US3548417 *5 sept. 196722 déc. 1970Kischer Jane NHeart valve having a flexible wall which rotates between open and closed positions
US3576176 *23 sept. 196927 avr. 1971Pickett John E PCooperative histologic tissue capsule and capsule rack
US3596292 *20 févr. 19693 août 1971Franklin InstituteHair implant structure
US3598127 *6 juin 196810 août 1971Wepsic James GCatheter having antibacterial substance therein provided with means permitting slow release of said substance
US3640269 *24 oct. 19698 févr. 1972Delgado Jose M RFluid-conducting instrument insertable in living organisms
US3640741 *24 févr. 19708 févr. 1972Hollister IncComposition containing gel
US3659600 *24 févr. 19702 mai 1972Charles River Foundation TheMagnetically operated capsule for administering drugs
US3678756 *23 sept. 196925 juil. 1972Hans W EstinCapsules and method for testing capsules for wall integrity
US3726972 *27 oct. 197010 avr. 1973Monsanto CoHalosilane-protein crosslink as ruminant feed material
US3797485 *26 mars 197119 mars 1974Alza CorpNovel drug delivery device for administering drug into blood circulation in blood vessel
US3804088 *31 juil. 197216 avr. 1974Lilly Co EliRemovable implantate for administering physiological active agents to animals
US3811444 *27 déc. 197221 mai 1974Alza CorpBioerodible ocular device
US3832458 *6 déc. 197127 août 1974River C FoundationHydrophilic silicone composition and method
US3873713 *2 juil. 197325 mars 1975Hoffmann La RocheStabilized particulate vitamin c composition
US3898701 *17 janv. 197412 août 1975Russa JosephImplantable heart valve
US3905360 *23 juil. 197316 sept. 1975Alza CorpIntrauterine device for governing the reproductive process
US3911911 *27 mars 197414 oct. 1975Reese Hospital MichaelAnti-fertility device
US3916898 *10 juil. 19704 nov. 1975Searle & CoAdministration of medicaments and the like
US3921636 *22 avr. 197425 nov. 1975Alza CorpNovel drug delivery device
US3934274 *29 oct. 197427 janv. 1976Hartley Jr John HDeflatable mammary augmentation prosthesis
US3944064 *26 oct. 197316 mars 1976Alza CorporationSelf-monitored device for releasing agent at functional rate
US3946106 *24 oct. 197423 mars 1976G. D. Searle & Co.Polysiloxanes
US3948262 *10 mars 19756 avr. 1976Alza CorporationNovel drug delivery device
US3967618 *6 mars 19756 juil. 1976Alza CorporationDrug delivery device
US3971376 *2 oct. 197427 juil. 1976Ceskoslovenska Akademie VedMethod and apparatus for introducing fluids into the body
US3987797 *11 déc. 197426 oct. 1976Ethicon, Inc.Antimicrobial sutures
US3992518 *29 sept. 197516 nov. 1976G. D. Searle & Co.Crosslinking silicone polymers
US4012497 *23 sept. 197515 mars 1977Schering AktiengesellschaftVaginal rings
US4053580 *20 sept. 197611 oct. 1977G. D. Searle & Co.Microsealed pharmaceutical delivery device
US4162676 *4 août 197731 juil. 1979Dow Corning CorporationCured silicone rubber and calcium hydroxide
US4191741 *22 sept. 19784 mars 1980Eli Lilly And CompanyRemovable drug implant
US4198976 *11 oct. 197722 avr. 1980The Procter & Gamble CompanyVaginal contraceptive
US4200090 *15 janv. 197929 avr. 1980The Procter & Gamble CompanyVaginal contraceptive and method of using
US4210644 *23 févr. 19781 juil. 1980The Johns Hopkins UniversityMale contraception
US4219016 *7 déc. 197826 août 1980The Procter & Gamble CompanyVaginal contraceptive
US4228032 *6 nov. 197814 oct. 1980Dow Corning CorporationSilicone rubber compounded with calcium hydroxide
US4230686 *23 déc. 197628 oct. 1980Schering AktiengesellschaftSustained release
US4264575 *8 avr. 198028 avr. 1981Eli Lilly And CompanyContraceptive methods and compositions
US4264576 *8 avr. 198028 avr. 1981Eli Lilly And CompanyContraceptive methods and compositions
US4264577 *8 avr. 198028 avr. 1981Eli Lilly And CompanyContraceptive methods and compositions
US4264578 *8 avr. 198028 avr. 1981Eli Lilly And CompanyContraceptive methods and compositions
US4298002 *10 sept. 19793 nov. 1981National Patent Development CorporationHydrogel of acrylic polymer allowing flow of steroids; grafting; glandular disorders; antibody inhibitors
US4301800 *19 mai 198024 nov. 1981Baxter Travenol Laboratories, Inc.Blood bags having an insert member
US4304010 *12 oct. 19798 déc. 1981Sumitomo Electric Industries, Ltd.Tubular polytetrafluoroethylene prosthesis with porous elastomer coating
US4304226 *3 mars 19808 déc. 1981The Procter & Gamble CompanyVaginal contraceptive
US4309776 *13 mai 198012 janv. 1982Ramon BerguerIntravascular implantation device and method of using the same
US4321711 *12 oct. 197930 mars 1982Sumitomo Electric Industries, Ltd.Polytetrafluroethylene containing an anticoagulatn conded to an elastomer cointaining an coagulant
US4341728 *20 déc. 197927 juil. 1982The Population Council, Inc.Method for making an IUD with shrinking of a medicated attachment onto a support
US4343788 *29 juin 197910 août 1982The Procter & Gamble CompanyAntimicrobial polymer compositions
US4344431 *4 août 198017 août 1982University Of DelawarePolymeric article for dispensing drugs
US4384960 *13 nov. 197924 mai 1983Polley R DIodine dispenser and method of dispensing iodine
US4392848 *25 juin 197912 juil. 1983The Procter & Gamble CompanyCatheterization
US4479795 *27 juil. 198230 oct. 1984The Procter & Gamble CompanyFor catheters
US4485814 *5 sept. 19794 déc. 1984Yoon In BOne-piece compound elastic occluding member
US4555398 *22 sept. 198326 nov. 1985Chisso CorporationThermosetting or thermoplastic resin mold
US4690683 *2 juil. 19851 sept. 1987Rutgers, The State University Of New JerseyTransdermal varapamil delivery device
US4731080 *20 mai 198615 mars 1988Galin Miles ACoated intraocular lens
US4803076 *4 sept. 19867 févr. 1989Pfizer Inc.Controlled release device for an active substance
US4888009 *31 oct. 198619 déc. 1989Abiomed, Inc.Prosthetic heart valve
US4888416 *30 mars 198719 déc. 1989International Minerals & Chemical Corp.Mixing with ionic detergent and drying
US4894231 *28 juil. 198716 janv. 1990Biomeasure, Inc.Therapeutic agent delivery system
US4898733 *4 nov. 19856 févr. 1990International Minerals & Chemical Corp.Layered, compression molded device for the sustained release of a beneficial agent
US4917685 *16 mai 198617 avr. 1990International Minerals & Chem. Corp.Porous membrane confining active materials and stabilizers
US4951657 *22 avr. 198828 août 1990Dow Corning CorporationBlock copolymer of polyurethane and polysiloxane
US4955899 *26 mai 198911 sept. 1990Impra, Inc.Longitudinally compliant vascular graft
US4960415 *18 nov. 19882 oct. 1990Merck Patent GmbhDevice for inserting in wounds and wound cavities
US4973320 *2 août 198827 nov. 1990Firma Carl FreudenbergPolysiloxane-urethane copolymer
US4985253 *16 févr. 199015 janv. 1991Sumitomo Pharmaceuticals Company, LimitedSustained release composition for pharmaceutical substances comprising a silicone elastomer carrier
US5008112 *16 déc. 198516 avr. 1991International Minerals & Chem. CorporationDevice for the extended delivery of diffusible agents
US5100422 *26 mai 198931 mars 1992Impra, Inc.Expanded polytetrafluoroethylene layer and nonporous elastomer coating for vascular patches
US5104400 *28 août 199114 avr. 1992Impra, Inc.Coating outer wall of polytetrafluoroethylene tube with elastomer; drying; opening tube; cutting patch from flat sheet
US5141748 *17 févr. 198925 août 1992Hoffmann-La Roche, Inc.Implant drug delivery device
US5152782 *26 mai 19896 oct. 1992Impra, Inc.Non-porous coated ptfe graft
US5182317 *17 juin 199126 janv. 1993Cardiopulmonics, Inc.Amine-Functional Siloxane, Polyoxyethylene Spacer, Bioactive Molecules
US5219580 *8 juin 199015 juin 1993Rhone-Poulenc ChimieThermoplastic silicone shaped articles for controlled release of iodine values to domestic water supplies
US5262451 *5 juil. 198816 nov. 1993Cardiopulmonics, Inc.Multifunctional thrombo-resistant coatings and methods of manufacture
US5340583 *6 mai 199323 août 1994Allergan, Inc.Case of polymeric material and antimicrobial compound, possibly covalently bonded; nonleachable
US5342693 *22 mars 199330 août 1994Cardiopulmonics, Inc.Bioactive molecules coavalently bonded to siloxane coating through polyether chains; membrane for blood gas exchange
US5422118 *21 sept. 19926 juin 1995Pure Pac, Inc.Transdermal administration of amines with minimal irritation and high transdermal flux rate
US5515117 *19 avr. 19947 mai 1996Allergan, Inc.Antimicrobial lenses and lens care systems
US5591445 *10 oct. 19957 janv. 1997Regents Of The University Of MinnesotaFor stimulating peristaltic contractions of intestines, barium chloride or neurotransmitter dispersed in silicone matrix
US5810836 *7 nov. 199622 sept. 1998Myocardial Stents, Inc.Device and method for trans myocardial revascularization (TMR)
US616880119 mars 19992 janv. 2001Cardiac Pacemakers, Inc.Controlled release drug delivery
US630478629 mars 199916 oct. 2001Cardiac Pacemakers, Inc.Implantable lead with dissolvable coating for improved fixation and extraction
US6476079 *23 déc. 19995 nov. 2002Leiras OyDevices for the delivery of drugs having antiprogestinic properties
US658436316 juil. 200124 juin 2003Cardiac Pacemakers, Inc.Implantable lead with dissolvable coating for improved fixation and extraction
US66452416 févr. 200111 nov. 2003Ernst Peter StreckerEndoprosthesis that can be percutaneously implanted in the patient's body
US67560486 sept. 199929 juin 2004Sumitomo Pharmaceuticals Company, LimitedLong time drug-sustained release preparation
US721728624 août 200615 mai 2007Cordis CorporationLocal delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent
US721897124 juin 200315 mai 2007Cardiac Pacemakers, Inc.Implantable lead with dissolvable coating for improved fixation and extraction
US722328628 sept. 200429 mai 2007Cordis CorporationLocal delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent
US722947324 août 200612 juin 2007Cordis CorporationLocal delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent
US724731231 oct. 200024 juil. 2007Dainippon Sumitomo Pharma Co., Ltd.Hydrophobic polymer carrier containing dispersed particles of an active ingredient that is slightly water soluble or insoluble (especially a vaccine), carbonate particles, and particles of a compound that reacts with the carbonate in an aqueous solution to generate CO2, which accelerates release rate
US730066221 avr. 200427 nov. 2007Cordis CorporationLocal delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography, lower systemic toxicity
US760136319 mars 200713 oct. 2009Dainippon Sumitomo Pharma Co., Ltd.Water solubility; silicones; vaccines
US762541023 janv. 20061 déc. 2009Boston Scientific Scimed, Inc.Stent device and method
US776307724 déc. 200327 juil. 2010Biomerix CorporationRepair of spinal annular defects and annulo-nucleoplasty regeneration
US780339517 mai 200428 sept. 2010Biomerix CorporationBiodurable, reticulated elastomeric matrices that are resiliently-compressible; crosslinked polycarbonate-urea-urethane, open-cell foam; tissue engineering; biodurable scaffolds; biocompatible; grafting; orthopedics; tissue repair and regeneration long-term
US806702220 juil. 200129 nov. 2011Boston Scientific Scimed, Inc.Therapeutic inhibitor of vascular smooth muscle cells
US809764227 févr. 200717 janv. 2012Boston Scientific Scimed, Inc.Therapeutic inhibitor of vascular smooth muscle cells
US813350128 févr. 200313 mars 2012Boston Scientific Scimed, Inc.Implantable or insertable medical devices for controlled drug delivery
US81586704 janv. 200717 avr. 2012Boston Scientific Scimed, Inc.Therapeutic inhibitor of vascular smooth muscle cells
US8197839 *1 juil. 200212 juin 2012Virbac CorporationA miniature coated tablet or covered rod implant; smaller size and larger payloads than immediate release tablets; veterinary medicine
US823604827 avr. 20047 août 2012Cordis CorporationDrug/drug delivery systems for the prevention and treatment of vascular disease
US830360928 sept. 20016 nov. 2012Cordis CorporationCoated medical devices
US8419793 *12 mars 201016 avr. 2013Mentor Worldwide LlcCoating with antimicrobial agents
US8420153 *19 sept. 200816 avr. 2013Mentor Worldwide LlcCoating with antimicrobial agents
US868542731 juil. 20021 avr. 2014Boston Scientific Scimed, Inc.Controlled drug delivery
US869126424 févr. 20128 avr. 2014Boston Scientific Scimed, Inc.Implantable or insertable medical devices for controlled drug delivery
US875098320 sept. 200410 juin 2014P Tech, LlcTherapeutic system
USRE28536 *4 mars 19712 sept. 1975 Animal husbandry
DE2547378A1 *23 oct. 197529 avr. 1976Searle & CoVorrichtung mit abgeschlossenen mikrokammern zur abgabe eines arzneimittels
DE2918522A1 *8 mai 197915 nov. 1979PfizerVerbessertes system bzw. verbesserte vorrichtung zur kontrollierten und kontinuierlichen abgabe von chemikalien waehrend einer laengeren zeitspanne
EP0013949A2 *18 janv. 19806 août 1980Hoechst AktiengesellschaftDepot body on the basis of silicon rubber and method for its preparation
EP0050867A1 *24 oct. 19815 mai 1982Schering AktiengesellschaftVaginal ring
EP0056697A2 *11 janv. 198228 juil. 1982Robert W. RandInjectable compositions suitable for use in inductively heating neoplasms
EP0219076A2 *10 oct. 198622 avr. 1987Sumitomo Pharmaceuticals Company, LimitedSustained release composition
EP1553899A2 *22 oct. 200320 juil. 2005The Biomerix CorporationMethod and system for intravesicular delivery of therapeutic agents
EP2089486A2 *20 nov. 200719 août 2009Steven J. FerryCoating system
WO1981001650A1 *24 nov. 198025 juin 1981Dow CorningSilicone gel-filled silicone rubber article possessing reduced surface-bleed
WO1986001415A1 *30 août 198513 mars 1986Geistlich Soehne AgDevice for inserting in wounds and wound cavities
WO1987000042A1 *27 juin 198615 janv. 1987Univ New JerseyTransdermal verapamil delivery device
WO1989000839A1 *27 juil. 19889 févr. 1989Biomeasure IncTherapeutic agent delivery system
WO1989012478A1 *21 juin 198928 déc. 1989Hansjoerg JustDilatation catheter
WO1990013332A1 *9 mai 199015 nov. 1990Cedars Sinai Medical CenterStent with sustained drug delivery
WO2000029464A1 *26 oct. 199925 mai 2000Ala Sorvari JuhaNovel membrane or matrix for controlling drug permeation
WO2006037182A16 oct. 200513 avr. 2006Agri Biotech Pty LtdAntibody production method
Classifications
Classification aux États-Unis424/424, 623/1.42, 206/.5, 206/5, 435/2
Classification internationaleA61K9/20, C08L83/04, A61M31/00
Classification coopérativeA61K9/2036, C08G77/20, C08G77/24, C08G77/18, C08L83/04, A61M31/002
Classification européenneA61K9/20H6D2, C08L83/04, A61M31/00D